Physiological and QoL Benefits of Qi-Gong in Post-acute Sequelae of Covid-19
QG-PASC
The Effects of Qi-gong on Physiology and Quality of Life in Patients with Post-acute Sequelae of Covid-19
2 other identifiers
interventional
80
1 country
2
Brief Summary
The goal of this clinical trial is to determine whether Qi-Gong can improve physiological function and quality of life (QoL) in individuals with post-acute sequelae of SARS-CoV-2 infection (PASC). Study Objectives: To assess whether Qi-Gong improves physiological function in individuals with PASC. To evaluate whether Qi-Gong enhances quality of life in individuals with PASC. Study Design: If a comparison group is included, researchers will compare Qi-Gong with standard care to assess its effectiveness. Participant Involvement: Practice Qi-Gong three times per week for three months. Record physiological data monthly.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Dec 2024
Shorter than P25 for not_applicable
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 2, 2024
CompletedFirst Submitted
Initial submission to the registry
February 15, 2025
CompletedFirst Posted
Study publicly available on registry
March 17, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 7, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
April 7, 2025
CompletedMarch 17, 2025
March 1, 2025
4 months
February 15, 2025
March 12, 2025
Conditions
Outcome Measures
Primary Outcomes (8)
Pulmonary Function Test (Forced vital capacity)
FVC，over 80% is better
From enrollment to the end of treatment at 12 weeks
Pulmonary Function Test (FEV1)
FEV1，over 80% is better
From enrollment to the end of treatment at 12 weeks
Pulmonary Function Test (FVCFEV1)
FVCFEV1，over 80% is better
From enrollment to the end of treatment at 12 weeks
Heart rate variability
Low Frequency,40%-60%
From enrollment to the end of treatment at 12 weeks
Heart rate variability
High Frequency,40%-60%
From enrollment to the end of treatment at 12 weeks
Heart rate variability
LF/HF,0.6-2.5
From enrollment to the end of treatment at 12 weeks
Heart rate variability
Heart rate variability ,25ms-70ms
From enrollment to the end of treatment at 12 weeks
Quality of Life(The short version of the World Health Organization Quality of Life ，WHOQOL-BREF)
WHOQOL-BREF 4 domains,and each one score is 4 - 20. more score more better
From enrollment to the end of treatment at 12 weeks
Study Arms (2)
Qi-Gong Group
EXPERIMENTALExperimental Group :Qi-Gong(yijinjing)
routine care Group
NO INTERVENTIONControl Group:routine care
Interventions
Eligibility Criteria
You may qualify if:
- PASC
- above 20 y/o
You may not qualify if:
- Those who cannot cooperate
- Severe schizophrenia
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- POCHIWUlead
Study Sites (2)
Renhe nursing home
New Taipei City, Taiwan
Fuxi nursing home
Taipei, Taiwan
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Mei-Hua Wang
National Taipei University of Nursing and Health Sciences
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- nurse、master's candidate
Study Record Dates
First Submitted
February 15, 2025
First Posted
March 17, 2025
Study Start
December 2, 2024
Primary Completion
April 7, 2025
Study Completion
April 7, 2025
Last Updated
March 17, 2025
Record last verified: 2025-03
Data Sharing
- IPD Sharing
- Will not share